Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2005-04-07

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM049110XPMID 15801838
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Toward the active conformations of rhodopsin and the β2‐adrenergic receptor

  2004cited by this paper
• Three-dimensional model for meta-II rhodopsin, an activated G-protein-coupled receptor.

  2003cited by this paper
• Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin.

  2003cited by this paper
• Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay

  2003cited by this paper
• A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.

  2002cited by this paper
• Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).

  2002cited by this paper
• Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents

  2002cited by this paper
• Lysophosphatidylcholine potentiates the mitogenic effect of various vasoactive compounds on rabbit aortic smooth muscle cells.

  2002cited by this paper
• Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor

  2002cited by this paper
• Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model.

  2002cited by this paper
• Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

  2002cited by this paper
• Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets?

  2002cited by this paper
• Urotensin II evokes potent vasoconstriction in humans in vivo

  2002cited by this paper
• G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin.

  2001cited by this paper
• Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors.

  2001cited by this paper
• Agonist-induced Conformational Changes at the Cytoplasmic Side of Transmembrane Segment 6 in the β2 Adrenergic Receptor Mapped by Site-selective Fluorescent Labeling*

  2001cited by this paper
• Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors.

  2001cited by this paper
• Cardiostimulant effects of urotensin‐II in human heart in vitro

  2001cited by this paper
• Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats

  2001cited by this paper
• Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat

  2000cited by this paper
• Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

  2000cited by this paper
• The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000

  2000cited by this paper
• Urotensin II: fish neuropeptide catches orphan receptor.

  2000cited by this paper
• Crystal structure of rhodopsin: A G protein-coupled receptor.

  2000cited by this paper
• Conformational Changes in Rhodopsin

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction

  1999cited by this paper
• Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors

  1999cited by this paper
• Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

  1998cited by this paper
• Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord.

  1998cited by this paper
• A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation.

  1998cited by this paper
• The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1998

  1998cited by this paper
• Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment*

  1997cited by this paper
• Barley lipid-transfer protein complexed with palmitoyl CoA: the structure reveals a hydrophobic binding site that can expand to fit both large and small lipid-like ligands.

  1997cited by this paper
• Interactions between Conserved Residues in Transmembrane Helices 1, 2, and 7 of the Thyrotropin-releasing Hormone Receptor*

  1997cited by this paper
• Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.

  1997cited by this paper
• Automated docking of flexible ligands: Applications of autodock

  1996cited by this paper
• Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state.

  1996cited by this paper
• Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice.

  1996cited by this paper
• Molecular architecture of G protein‐coupled receptors

  1996cited by this paper
• Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates.

  1996cited by this paper
• Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin

  1996cited by this paper
• AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules

  1995cited by this paper
• The crystal structure of bluetongue virus VP7

  1995cited by this paper
• A second generation force field for the simulation of proteins

  1995cited by this paper
• Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice.

  1995cited by this paper
• Related Contribution of Specific Helix 2 and 7 Residues to Conformational Activation of the Serotonin 5-HT2A Receptor (*)

  1995cited by this paper
• Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors.

  1995cited by this paper
• [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors

  1995cited by this paper
• CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

  1994cited by this paper
• A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor.

  1994cited by this paper
• Structure and function of receptors coupled to G proteins.

  1994cited by this paper
• Polarity conserved positions in transmembrane domains of G‐protein coupled receptors and bacteriorhodopsin

  1994cited by this paper
• Locating ligand-binding sites in 7TM receptors by protein engineering.

  1994cited by this paper
• The three-dimensional structure of N-acetylneuraminate lyase from Escherichia coli.

  1994cited by this paper
• A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice.

  1994cited by this paper
• Molecular dynamics simulation of a bilayer of 200 lipids in the gel and in the liquid crystal phase

  1993cited by this paper
• Prediction of protein secondary structure at better than 70% accuracy.

  1993cited by this paper
• PROCHECK: a program to check the stereochemical quality of protein structures

  1993cited by this paper
• Stereochemical quality of protein structure coordinates

  1992cited by this paper
• Allele-specific activation of genetically engineered receptors.

  1991cited by this paper
• Modelling the polypeptide backbone with 'spare parts' from known protein structures.

  1989cited by this paper
• Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.

  1989cited by this paper
• Contraction of major artery segments of rat by fish neuropeptide urotensin II.

  1987cited by this paper
• Using known substructures in protein model building and crystallography.

  1986cited by this paper
• Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model

  1985cited by this paper
• A Broyden—Fletcher—Goldfarb—Shanno optimization procedure for molecular geometries

  1985cited by this paper
• Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes.

  1985cited by this paper
• Molecular dynamics with coupling to an external bath

  1984cited by this paper
• ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES

  1980cited by this paper
• The Cambridge Crystallographic Data Centre: computer-based search, retrieval, analysis and display of information

  1979cited by this paper
• Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes

  1977cited by this paper

• Efficacy of Urotensin II in Cardiovascular System

  2018cites this paper
• Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects

  2018cites this paper
• Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II.

  2017cites this paper
• Synthèse en phase solide de pyrrolo[3,2-e][1,4]diazépin-2-ones modulateurs du système urotensinergétique

  2017cites this paper
• Plasma urotensin-2 level and Thr21Met but not Ser89Asn polymorphisms of the urotensin-2 gene are associated with migraines

  2016influential citation
• Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist.

  2016cites this paper
• International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

  2015influential citation
• Comparative Distribution and In Vitro Activities of the Urotensin II-Related Peptides URP1 and URP2 in Zebrafish: Evidence for Their Colocalization in Spinal Cerebrospinal Fluid-Contacting Neurons

  2015cites this paper
• De Novo Conception of Small Molecule Modulators Based on Endogenous Peptide Ligands: Pyrrolodiazepin-2-one γ-Turn Mimics That Differentially Modulate Urotensin II Receptor-Mediated Vasoconstriction ex Vivo.

  2015cites this paper
• Palosuran: clinical pharmacology of a urotensin-II receptor antagonist in Type 2 Diabetes Mellitus

  2015influential citation
• Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures

  2013cites this paper
• Biochemical and pharmacological characterization of nuclear urotensin‐II binding sites in rat heart

  2012influential citation
• Structural insights into human GPCR protein OA1: a computational perspective

  2012cites this paper
• Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.

  2012cites this paper
• Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells

  2011cites this paper
• Update 1 of: computational modeling approaches to structure-function analysis of G protein-coupled receptors.

  2011cites this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cites this paper
• New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.

  2009cites this paper
• Human urotensin-II receptor desensitisation

  2009cites this paper
• Structure–activity relationship study on Tyr9 of urotensin-II(4–11): Identification of a partial agonist of the UT receptor

  2009cites this paper
• Pharmacokinetics and Pharmacodynamics of the Urotensin‐II Receptor Antagonist Palosuran in Healthy Male Subjects

  2009cites this paper
• Automated synthesis of the generic peptide labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate and application to (18)F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography.

  2008cites this paper
• Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?

  2008cites this paper
• Three‐dimensional model of the human urotensin‐II receptor: Docking of human urotensin‐II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model

  2008cites this paper
• Structure–activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11)

  2008cites this paper
• Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.

  2008cites this paper
• Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II.

  2008cites this paper
• Synthèse de ligands du récepteur de l'Urotensine II et des récepteurs de la Mélatonine : composés à noyau pyrido[2,3-d]pyrimidine ou imidazo[1,2-a]pyridine

  2008cites this paper
• Nonpeptidic ligands for peptide-activated G protein-coupled receptors.

  2007cites this paper
• Definition of New Pharmacophores for Nonpeptide Antagonists of Human Urotensin-II. Comparison with the 3D-structure of Human Urotensin-II and URP

  2007cites this paper
• An overview of recent developments in GPCR modelling: methods and validation

  2006cites this paper
• Novel potent and efficacious nonpeptidic urotensin II receptor agonists.

  2006cites this paper
• Design and synthesis of potent cystine-free cyclic hexapeptide agonists at the human urotensin receptor.

  2006cites this paper
• Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide.

  2006cites this paper
• Urotensin-II receptor antagonists.

  2006cites this paper
• Ligand‐supported homology modeling of the human angiotensin II type 1 (AT1) receptor: Insights into the molecular determinants of telmisartan binding

  2006cites this paper
• Homology modeling of G-protein-coupled receptors and implications in drug design.

  2006cites this paper
• Computational modeling approaches to structure-function analysis of G protein-coupled receptors.

  2005cites this paper